The sensitivity of HRDetect for predicting BRCA1/2 mutation in the validation cohort was 86% in ER+/HER2- breast cancer patients [89] and showed sensitivity to detect PALB2 biallelic inactivation or RAD51C hypermethylation, and to reclassify BRCA1/2 VUS as germline PV [90]. Here, RAD51C is linked to breast carcinoma.